ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
DSM and Caliber Therapeutics will collaborate on the development of a novel drug delivery balloon catheter that enables the controlled and sustained release of drugs to treat vascular diseases. The partners will combine DSM's Trancerta drug delivery technology, based on resorbable materials, with balloon and catheter technologies from Caliber. Separately, DSM and the French firm LibraGen will codevelop new omega-transaminases for production of chiral amines. LibraGen will discover new enzymes capable of converting ketones into optically pure amines, and DSM will produce them at industrial scale.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X